Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

7.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis to ameliorate cardiac remodeling in HFpEF.

Experimental & molecular medicine·2026
Same author

Real-World Evidence for Expanding the Criteria for Endoscopic Resection in Submucosal Gastric Cancer: The Role of Invasion Width.

Journal of gastric cancer·2026
Same author

Clinico-Pathologic Features of Adult Erdheim-Chester Disease in South Korea: A Multicenter Retrospective Study (KCSG LY22-15).

Cancer research and treatment·2026
Same author

Ssu72 phosphatase orchestrates obesogenic adipogenesis and metabolic homeostasis during nutrient excess.

Cell death and differentiation·2026
Same author

A proof-of-concept automated method for accurate skin dosimetry: correcting overestimated surface dose measurements.

Physics in medicine and biology·2026
Same author

Rewiring Glycolysis in Cancer: From Tumor Initiation to Therapeutic Vulnerabilities.

Cells·2026

Related Experiment Video

Updated: Oct 6, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function.

Jihyun Park1, Si-Yeon Lee2, Yoon Jeon2,3

  • 1Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.

Cancer Immunology Research
|January 21, 2022
PubMed
Summary

Pellino1 (Peli1) negatively regulates anti-tumor CD8+ T cell responses. Reducing Peli1 enhances T cell function and prevents exhaustion, suggesting Peli1 as a therapeutic target for cancer immunotherapy.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.3K

Related Experiment Videos

Last Updated: Oct 6, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.3K

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • CD8+ T cells are crucial for tumor elimination.
  • Mechanisms maintaining CD8+ T cell effector function in tumors are not fully understood.
  • Pellino1 (Peli1) is an E3 ligase involved in innate immunity signaling.

Purpose of the Study:

  • To investigate the role of Peli1 in CD8+ T cell responses within the tumor microenvironment.
  • To elucidate the molecular mechanisms by which Peli1 affects anti-tumor immunity.
  • To evaluate Peli1 as a potential therapeutic target for cancer immunotherapy.

Main Methods:

  • Analysis of Peli1 expression in tumor-infiltrating lymphocytes (TILs).
  • Assessment of CD8+ TIL function in Peli1-deficient versus wild-type mice.
  • Investigation of Peli1 interaction with protein kinase C-theta (PKCθ) using ubiquitination assays.

Main Results:

  • Peli1 expression is elevated in CD8+ TILs and correlates with tumor risk.
  • Peli1 deficiency enhances CD8+ TIL maintenance, effector function, and prevents T cell exhaustion.
  • Peli1 directly interacts with PKCθ and inhibits its signaling pathway via ubiquitination and degradation.
  • The Peli1-PKCθ axis suppresses anti-tumor CD8+ T cell activity.

Conclusions:

  • The Peli1-PKCθ signaling pathway is a key negative regulator of anti-tumor CD8+ T cell immunity.
  • Targeting Peli1 presents a promising therapeutic strategy to enhance cytotoxic T cell activity against tumors.